Shandong Sito Bio-technology Co Ltd
SZSE:300583
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shandong Sito Bio-technology Co Ltd
Operating Income
Shandong Sito Bio-technology Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shandong Sito Bio-technology Co Ltd
SZSE:300583
|
Operating Income
-¥173.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Operating Income
¥6.6B
|
CAGR 3-Years
37%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Operating Income
¥9B
|
CAGR 3-Years
42%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Operating Income
¥4.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Operating Income
¥7.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
35%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Operating Income
¥3.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
203%
|
CAGR 10-Years
N/A
|
|
Shandong Sito Bio-technology Co Ltd
Glance View
Shandong Sito Bio-technology Co., Ltd. provides steroidal pharmaceutical raw materials using biotechnology. The company is headquartered in Heze, Shandong and currently employs 1,140 full-time employees. The company went IPO on 2017-01-06. The firm operates three product segments. The Steroid Raw Materials segment is engaged in the manufacturing of steroid raw materials using genetic engineering technology and microbial transformation technology, such as androstenedione, androstenedione, 9-hydroxyandrostenedione, hydroxyprogesterone and so on. The firm also operates Steroidal Finished Drug segment and Non-Steroidal Finished Drug segment through its subsidiary.
See Also
What is Shandong Sito Bio-technology Co Ltd's Operating Income?
Operating Income
-173.4m
CNY
Based on the financial report for Sep 30, 2025, Shandong Sito Bio-technology Co Ltd's Operating Income amounts to -173.4m CNY.
What is Shandong Sito Bio-technology Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-24%
